Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 12 | 2025 | 1273 | 1.090 |
Why?
|
| Graft vs Host Disease | 4 | 2023 | 688 | 0.410 |
Why?
|
| Neuroblastoma | 2 | 2025 | 547 | 0.380 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 23 | 0.330 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2023 | 57 | 0.300 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2018 | 107 | 0.270 |
Why?
|
| Cell Movement | 1 | 2010 | 873 | 0.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 870 | 0.240 |
Why?
|
| Transplantation Conditioning | 5 | 2023 | 327 | 0.240 |
Why?
|
| Central Venous Catheters | 1 | 2025 | 50 | 0.220 |
Why?
|
| Catheterization, Central Venous | 1 | 2025 | 136 | 0.210 |
Why?
|
| Stem Cell Transplantation | 1 | 2025 | 224 | 0.210 |
Why?
|
| Whole-Body Irradiation | 2 | 2015 | 61 | 0.210 |
Why?
|
| Device Removal | 1 | 2025 | 222 | 0.200 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 26 | 0.200 |
Why?
|
| Lymphocyte Depletion | 2 | 2015 | 124 | 0.200 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2024 | 150 | 0.200 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2010 | 950 | 0.190 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 49 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 1707 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 130 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 154 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 306 | 0.140 |
Why?
|
| Immune Reconstitution | 1 | 2018 | 5 | 0.140 |
Why?
|
| Transplantation, Homologous | 5 | 2023 | 668 | 0.140 |
Why?
|
| Cytomegalovirus | 2 | 2016 | 258 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 239 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 332 | 0.130 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2016 | 16 | 0.120 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 23 | 0.110 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 44 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 501 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2016 | 451 | 0.110 |
Why?
|
| Child, Preschool | 9 | 2025 | 15005 | 0.110 |
Why?
|
| Child | 11 | 2025 | 26174 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17541 | 0.100 |
Why?
|
| Transplantation, Autologous | 2 | 2025 | 253 | 0.100 |
Why?
|
| DNA Viruses | 1 | 2013 | 30 | 0.100 |
Why?
|
| Infant | 7 | 2025 | 13269 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 76 | 0.090 |
Why?
|
| Alemtuzumab | 2 | 2023 | 89 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 235 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 2013 | 146 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2012 | 84 | 0.090 |
Why?
|
| Adolescent | 8 | 2025 | 20800 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 510 | 0.080 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 112 | 0.080 |
Why?
|
| Humans | 16 | 2025 | 130085 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 271 | 0.080 |
Why?
|
| Transgenes | 1 | 2010 | 316 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2010 | 583 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 688 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12821 | 0.070 |
Why?
|
| Unrelated Donors | 2 | 2021 | 72 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 499 | 0.060 |
Why?
|
| Recurrence | 2 | 2023 | 1475 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 118 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3114 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 222 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 51 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3713 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 148 | 0.050 |
Why?
|
| Registries | 2 | 2024 | 1607 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.040 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Young Adult | 3 | 2022 | 9981 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 171 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 708 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 430 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 325 | 0.030 |
Why?
|
| Male | 6 | 2025 | 64386 | 0.030 |
Why?
|
| Colorado | 1 | 2016 | 20 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 2016 | 32 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1265 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 33660 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 306 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 408 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1325 | 0.030 |
Why?
|
| Female | 5 | 2025 | 70246 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 462 | 0.020 |
Why?
|
| Mice | 1 | 2010 | 18160 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 1453 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 20821 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 314 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3655 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2012 | 5 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 2588 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6402 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 1153 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1481 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2013 | 394 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 656 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 221 | 0.020 |
Why?
|
| Middle Aged | 2 | 2022 | 28314 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 581 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 289 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 639 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 31011 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 4035 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3321 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 3782 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5167 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8554 | 0.010 |
Why?
|
| United States | 1 | 2018 | 11896 | 0.010 |
Why?
|